modelClofazimine

Diagram of Clofazimine

Extends from Pharmacolibrary.Drugs.ATC.J.J04BA01.

Information

name:Clofazimine
ATC code:J04BA01
route:oral
compartments:2
dosage:100mg
volume of distribution:1050L
clearance:0.48L/h
other parameters in model implementation

Clofazimine is a riminophenazine antibiotic primarily used for the treatment of leprosy (Hansen's disease), especially for multibacillary forms and as part of multidrug therapy. It is also occasionally used off-label for some mycobacterial infections. Clofazimine is approved and used in several countries but is not approved for all mycobacterial infections. Its use is limited due to side effects such as skin discoloration and gastrointestinal symptoms.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy male volunteers, following oral administration of clofazimine at steady state.

References

  1. Zhang, CX, et al., & Arnold, SLM (2022). Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis. Antimicrobial agents and chemotherapy 66(1) e0156021–None. DOI:10.1128/AAC.01560-21 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34748385

  2. Stadler, JAM, et al., & Wasserman, S (2023). Clofazimine for the treatment of tuberculosis. Frontiers in pharmacology 14 1100488–None. DOI:10.3389/fphar.2023.1100488 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36817137

  3. Zhang, CX, et al., & Arnold, SLM (2024). Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics. CPT: pharmacometrics & systems pharmacology 13(3) 410–423. DOI:10.1002/psp4.13092 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38164114

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)